Other substances

Human amnionic fluid

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Human amnionic fluid is a non-antigenic solution with potential use as a bioscaffold for the treatment of a variety of conditions (e.g. burns, nerve regeneration, or tendon repair) (Selzman et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
A pilot trial of human amniotic fluid for the treatment of COVID-19
Case series Mixed substance 		ICU patients 1.34

No serious adverse events were noted. 9 out of 10 patients (admitted to ICU) survived. In some of the patients who received a higher intravenous dose of hAF the levels of CRP decreased and this decrease was associated with clinical improvement. Sample size: 10. Dosage: Original design (4 patients): 3 cc IV and 3 cc nebulized for 5 days in mechanically ventilated patients; 3 cc nebulized for 5 days in non-mechanically ventilated patients. Modified design (6 patients): 10 cc IV daily for 5 days. Endpoints: Hospital and ICU stay length, ventilator-free days, and supplemental oxygen need at discharge (primary outcomes).


 Jan/22/2021
Export (.csv)